Legend Biotech Reports First Quarter 2022 Financial Results and Recent HighlightsBusiness Wire • 06/01/22
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire • 05/31/22
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple MyelomaBusiness Wire • 05/26/22
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHABusiness Wire • 05/18/22
Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-TBusiness Wire • 04/21/22
Legend Biotech Announces Appointment of Global Head of Research and Early DevelopmentBusiness Wire • 04/01/22
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple MyelomaBusiness Wire • 03/25/22
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent HighlightsBusiness Wire • 03/18/22
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple MyelomaBusiness Wire • 03/01/22
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021Business Wire • 02/18/22
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901Business Wire • 02/15/22
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with JanssenBusiness Wire • 02/11/22
Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/22
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of DirectorsBusiness Wire • 12/30/21
Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple MyelomaBusiness Wire • 12/13/21